Literature DB >> 17388990

A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.

S N Illarioshkin1, M I Shadrina, P A Slominsky, E V Bespalova, T B Zagorovskaya, G Kh Bagyeva, E D Markova, S A Limborska, I A Ivanova-Smolenskaya.   

Abstract

A PARK8 form of Parkinson's disease (PD) is caused by a novel gene, leucine-rich repeat kinase 2 (LRRK2), and a single mutation G2019S was found in a proportion of LRRK2-associated cases of diverse ethnic origins. We performed the LRRK2 G2019S mutation analysis in 304 Russian patients with PD, including 291 sporadic and 13 autosomal dominant cases. The frequency of the LRRK2 G2019S was 0.7% amongst the sporadic patients (2/291) and 7.7% amongst familial PD (1/13). The mutation was also found in three unaffected relatives and absent in 700 control chromosomes. One patient carrying the LRRK2 G2019S was found earlier to have an additional mutation, a heterozygous duplication of exon 5 of the parkin gene. All patients carrying the LRRK2 G2019S exhibited typical levodopa-responsive parkinsonism, and severe levodopa-induced dyskinesia was observed in the patient carrying the LRRK2 and parkin mutations. There was notable variability in ages of the disease onset in G2019S carriers not explained by APOE genotypes. Two subsets of G2019S-positive patients had different PARK8 haplotypes suggesting that the LRRK2 G2019S in Russian patients had arisen independently on different chromosomes. Identification of common LRRK2 mutations in some PD patients without an overt family history has notable implications for genetic counseling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17388990     DOI: 10.1111/j.1468-1331.2007.01685.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  8 in total

Review 1.  The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Avner Thaler; Elissa Ash; Ziv Gan-Or; Avi Orr-Urtreger; Nir Giladi
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

Review 2.  Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update.

Authors:  Karen Nuytemans; Jessie Theuns; Marc Cruts; Christine Van Broeckhoven
Journal:  Hum Mutat       Date:  2010-07       Impact factor: 4.878

Review 3.  The role of the LRRK2 gene in Parkinsonism.

Authors:  Jie-Qiong Li; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurodegener       Date:  2014-11-12       Impact factor: 14.195

4.  Generation of iPSCs carrying a common LRRK2 risk allele for in vitro modeling of idiopathic Parkinson's disease.

Authors:  Lara Marrone; Christine Bus; David Schöndorf; Julia Catherine Fitzgerald; Manuela Kübler; Benjamin Schmid; Peter Reinhardt; Lydia Reinhardt; Michela Deleidi; Tanya Levin; Andrea Meixner; Barbara Klink; Michael Glatza; Christian Johannes Gloeckner; Thomas Gasser; Jared Sterneckert
Journal:  PLoS One       Date:  2018-03-07       Impact factor: 3.240

5.  Increased expression of pathological markers in Parkinson's disease dementia post-mortem brains compared to dementia with Lewy bodies.

Authors:  Haitao Tu; Zhi Wei Zhang; Lifeng Qiu; Yuning Lin; Mei Jiang; Sook-Yoong Chia; Yanfei Wei; Adeline S L Ng; Richard Reynolds; Eng-King Tan; Li Zeng
Journal:  BMC Neurosci       Date:  2022-01-04       Impact factor: 3.288

6.  Reduced Immunosenescence of Peripheral Blood T Cells in Parkinson's Disease with CMV Infection Background.

Authors:  Julia D Vavilova; Anna A Boyko; Natalya V Ponomareva; Vitaly F Fokin; Ekaterina Y Fedotova; Maria A Streltsova; Sofya A Kust; Maria V Grechikhina; Ekaterina V Bril; Olga S Zimnyakova; Elena I Kovalenko; Alexander M Sapozhnikov
Journal:  Int J Mol Sci       Date:  2021-12-04       Impact factor: 5.923

7.  Alterations in Proteostasis System Components in Peripheral Blood Mononuclear Cells in Parkinson Disease: Focusing on the HSP70 and p62 Levels.

Authors:  Julia D Vavilova; Anna A Boyko; Natalya I Troyanova; Natalya V Ponomareva; Vitaly F Fokin; Ekaterina Y Fedotova; Maria A Streltsova; Sofya A Kust; Maria V Grechikhina; Olga A Shustova; Tatyana L Azhikina; Elena I Kovalenko; Alexander M Sapozhnikov
Journal:  Biomolecules       Date:  2022-03-24

8.  Analysis of PRKN Variants and Clinical Features in Polish Patients with Parkinson's Disease.

Authors:  Anna Oczkowska; Jolanta Florczak-Wyspianska; Agnieszka Permoda-Osip; Michal Owecki; Margarita Lianeri; Wojciech Kozubski; Jolanta Dorszewska
Journal:  Curr Genomics       Date:  2015-08       Impact factor: 2.236

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.